NOTE TO READERS: KHN's First Edition will not be published Feb. 20. Look for it again in your inbox Feb. 21. Here's today's early morning highlights from the major news organizations.
Kaiser Health News: Congressman’s Ties To Foreign Biotech Draw Criticism
Rachel Bluth and Emily Kopp report: "When a small Australian biotechnology company, Innate Immunotherapeutics, needed a clinical trial for an experimental drug it hoped to turn into a huge moneymaker, the company landed a U.S. partner where it had high-level connections: Roswell Park Cancer Institute in Buffalo, N.Y. The company is partly owned by Rep. Chris Collins, a wealthy Republican entrepreneur from Buffalo, whose enthusiasm for Innate helped persuade others to invest." (Bluth and Kopp, 2/17)